Park Square Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Park Square Financial Group's XBI Position: Q3 2025 in Review
Park Square Financial Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 789 shares — an estimated $65.4K sold.
Park Square Financial Group first reported a position in XBI in Q4 2024 and held it in 3 quarters. The position peaked at $97.3K in Q4 2024. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.
- Park Square Financial Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
- Park Square Financial Group sold 789 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $65.4K.
- Park Square Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 3 quarters.
- Park Square Financial Group's State Street SPDR S&P Biotech ETF position peaked at $97.3K in Q4 2024.
- 656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.
Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.